These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
197 related articles for article (PubMed ID: 29254734)
1. Eteplirsen for paediatric patients with Duchenne muscular dystrophy: A pooled-analysis. Randeree L; Eslick GD J Clin Neurosci; 2018 Mar; 49():1-6. PubMed ID: 29254734 [TBL] [Abstract][Full Text] [Related]
2. Eteplirsen for the treatment of Duchenne muscular dystrophy. Mendell JR; Rodino-Klapac LR; Sahenk Z; Roush K; Bird L; Lowes LP; Alfano L; Gomez AM; Lewis S; Kota J; Malik V; Shontz K; Walker CM; Flanigan KM; Corridore M; Kean JR; Allen HD; Shilling C; Melia KR; Sazani P; Saoud JB; Kaye EM; Ann Neurol; 2013 Nov; 74(5):637-47. PubMed ID: 23907995 [TBL] [Abstract][Full Text] [Related]
3. Comparison of Long-term Ambulatory Function in Patients with Duchenne Muscular Dystrophy Treated with Eteplirsen and Matched Natural History Controls. Mendell JR; Khan N; Sha N; Eliopoulos H; McDonald CM; Goemans N; Mercuri E; Lowes LP; Alfano LN; J Neuromuscul Dis; 2021; 8(4):469-479. PubMed ID: 33523015 [TBL] [Abstract][Full Text] [Related]
4. Eteplirsen in the treatment of Duchenne muscular dystrophy. Lim KR; Maruyama R; Yokota T Drug Des Devel Ther; 2017; 11():533-545. PubMed ID: 28280301 [TBL] [Abstract][Full Text] [Related]
8. Eteplirsen: First Global Approval. Syed YY Drugs; 2016 Nov; 76(17):1699-1704. PubMed ID: 27807823 [TBL] [Abstract][Full Text] [Related]
9. Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy. Mendell JR; Goemans N; Lowes LP; Alfano LN; Berry K; Shao J; Kaye EM; Mercuri E; Ann Neurol; 2016 Feb; 79(2):257-71. PubMed ID: 26573217 [TBL] [Abstract][Full Text] [Related]
10. Long-term treatment with eteplirsen in nonambulatory patients with Duchenne muscular dystrophy. Alfano LN; Charleston JS; Connolly AM; Cripe L; Donoghue C; Dracker R; Dworzak J; Eliopoulos H; Frank DE; Lewis S; Lucas K; Lynch J; Milici AJ; Flynt A; Naughton E; Rodino-Klapac LR; Sahenk Z; Schnell FJ; Young GD; Mendell JR; Lowes LP Medicine (Baltimore); 2019 Jun; 98(26):e15858. PubMed ID: 31261494 [TBL] [Abstract][Full Text] [Related]
11. FDA Approves Eteplirsen for Duchenne Muscular Dystrophy: The Next Chapter in the Eteplirsen Saga. Aartsma-Rus A; Krieg AM Nucleic Acid Ther; 2017 Feb; 27(1):1-3. PubMed ID: 27929755 [No Abstract] [Full Text] [Related]
13. Long-Term Pulmonary Function in Duchenne Muscular Dystrophy: Comparison of Eteplirsen-Treated Patients to Natural History. Kinane TB; Mayer OH; Duda PW; Lowes LP; Moody SL; Mendell JR J Neuromuscul Dis; 2018; 5(1):47-58. PubMed ID: 29278896 [TBL] [Abstract][Full Text] [Related]
14. Exon skipping for Duchenne muscular dystrophy: a systematic review and meta-analysis. Shimizu-Motohashi Y; Murakami T; Kimura E; Komaki H; Watanabe N Orphanet J Rare Dis; 2018 Jun; 13(1):93. PubMed ID: 29907124 [TBL] [Abstract][Full Text] [Related]
15. A Combined Prospective and Retrospective Comparison of Long-Term Functional Outcomes Suggests Delayed Loss of Ambulation and Pulmonary Decline with Long-Term Eteplirsen Treatment. Mitelman O; Abdel-Hamid HZ; Byrne BJ; Connolly AM; Heydemann P; Proud C; Shieh PB; Wagner KR; Dugar A; Santra S; Signorovitch J; Goemans N; ; McDonald CM; ; Mercuri E; ; Mendell JR J Neuromuscul Dis; 2022; 9(1):39-52. PubMed ID: 34420980 [TBL] [Abstract][Full Text] [Related]
16. Safety, tolerability and pharmacokinetics of eteplirsen in young boys aged 6-48 months with Duchenne muscular dystrophy amenable to exon 51 skipping. Mercuri E; Seferian AM; Servais L; Deconinck N; Stevenson H; Ni X; Zhang W; East L; Yonren S; Muntoni F; Neuromuscul Disord; 2023 Jun; 33(6):476-483. PubMed ID: 37207382 [TBL] [Abstract][Full Text] [Related]
17. Restorative treatments of dystrophin expression in Duchenne muscular dystrophy: A systematic review. Pascual-Morena C; Cavero-Redondo I; Álvarez-Bueno C; Mesas AE; Pozuelo-Carrascosa D; Martínez-Vizcaíno V Ann Clin Transl Neurol; 2020 Sep; 7(9):1738-1752. PubMed ID: 33325654 [TBL] [Abstract][Full Text] [Related]
18. Survival among patients receiving eteplirsen for up to 8 years for the treatment of Duchenne muscular dystrophy and contextualization with natural history controls. Iff J; Done N; Tuttle E; Zhong Y; Wei F; Darras BT; McDonald CM; Mercuri E; Muntoni F Muscle Nerve; 2024 Jul; 70(1):60-70. PubMed ID: 38482981 [TBL] [Abstract][Full Text] [Related]
19. A Sequel to the Eteplirsen Saga: Eteplirsen Is Approved in the United States but Was Not Approved in Europe. Aartsma-Rus A; Goemans N Nucleic Acid Ther; 2019 Feb; 29(1):13-15. PubMed ID: 30526286 [TBL] [Abstract][Full Text] [Related]
20. Eteplirsen for the Treatment of Duchenne Muscular Dystrophy: Quality of Evidence Concerns-an Alternative Viewpoint. Irwin AN; Herink MC Pharmacotherapy; 2017 Oct; 37(10):e109-e111. PubMed ID: 28741800 [No Abstract] [Full Text] [Related] [Next] [New Search]